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A Bistable Switch in Virus Dynamics
Can Explain the Differences in
Disease Outcome Following SIV
Infections in Rhesus Macaques
Stanca M. Ciupe 1*, Christopher J. Miller 2 and Jonathan E. Forde 3
1Department of Mathematics, Virginia Tech, Blacksburg, VA, United States, 2Department of Pathology, Microbiology, and
Immunology, School of Veterinary Medicine, Center for Comparative Medicine and California National Primate Research
Center, University of California, Davis, Davis, CA, United States, 3Department of Mathematics and Computer Science,
Hobart and Williams Smith Colleges, Geneva, NY, United States
Experimental studies have shown that the size and infectious-stage of viral inoculum
influence disease outcomes in rhesus macaques infected with simian immunodeficiency
virus. The possible contribution to disease outcome of antibody developed after
transmission and/or present in the inoculum in free or bound form is not understood.
In this study, we develop a mathematical model of virus-antibody immune complex
formation and use it to predict their role in transmission and protection. The model
exhibits a bistable switch between clearance and persistence states. We fitted it to
temporal virus data and estimated the parameter values for free virus infectivity rate
and antibody carrying capacity for which the model transitions between virus clearance
and persistence when the initial conditions (in particular the ratio of immune complexes
to free virus) vary. We used these results to quantify the minimum virus amount in the
inoculum needed to establish persistent infections in the presence and absence of
protective antibodies.
Keywords: SIV, immune complexes, mathematical model, bistable dynamics, stochastic model
INTRODUCTION
The humoral immune response is one of the first barriers against infecting pathogens and forms
the basis for most vaccines that are currently in use (Plotkin, 2008; Deal and Balazs, 2015).
The rapidly mutating human immunodeficiency virus (HIV), however, evades humoral immune
responses in most human infections due to difficulties in eliciting neutralizing antibodies that are
effective against the enormous diversity of virus strains (Haynes, 2015). In a few cases broadly
neutralizing antibodies (bnAbs) are produced, but they appear 2–4 years following infection (Gray
et al., 2011; Tomaras et al., 2011), are ineffective against co-circulating virus strains, and have
unusual traits such as autoreactivity and high levels of somatic hypermutations (Mascola and
Haynes, 2013). Inducing protective antibodies in vivo is challenging (Mascola and Haynes, 2013;
Haynes, 2015), with the partially successful RV144 vaccine clinical trial offering a 31.2% decrease
in transmission through non-neutralizing antibody dependent cellular toxicity-mediated responses
(ADCC) (Rerks-Ngarm et al., 2009; Tomaras et al., 2013; Pollara et al., 2014).
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Animal models have proven useful in examining the
mechanisms of virus-antibody interactions that lead to
protection against HIV infections. Studies using the chimeric
simian-human rhesus macaque model (SHIV) have shown that
passive transfer of broadly neutralizing monoclonal antibodies
(bnMAbs) can induce protection against mucosal challenge
(Moldt et al., 2012). The protection is dependent on the ratio
between the challenge dose and the concentration of broadly
neutralizing antibodies in the serum (Mascola et al., 1999),
the breadth and potency of bnMAbs (Walker et al., 2011;
Moldt et al., 2012), as well as the timing of antibody infusion
(Nishimura et al., 2003). The potential for inducing neutralizing
antibodies that correlate with protection in vivo has been shown
during simian immunodeficiency virus (SIV) infections of ENV-
vaccinated rhesus macaques (Letvin et al., 2011), suggesting that
it may be possible to elicit antibody-mediated protection through
vaccination. Understanding the properties of antibodies, such as
concentration and avidity needed for protection based on known
virus count in the inoculum, is important information that can
guide vaccine design.
In 2009, Ma et al. used SIV infection in rhesus macaques
to examine the connection between infection outcome, the
size of the challenge inoculum and the disease stage in the
SIV infected animals used as donors (Ma et al., 2009). They
found that ∼20 viral RNA (vRNA) copies titrated from a
plasma pool containing virus collected during the ramp-up-
stage of infection in donor animals are needed to successfully
infect recipient animals. By contrast, ∼1,500 vRNA copies
titrated from a plasma pool containing virus collected during
the set-point-stage of infection in donor animals are needed
to establish infection in recipient animals. This led to the
conclusion that the virus infectivity decreases over time due
to a combination of virological and immunological factors. In
Vaidya et al. (2010) used mathematical models to quantify the
decrease in infectivity during the ramp-up and set-point infection
and found that the decrease happens during both acute and
chronic stages with a sharper decrease during acute infections.
They did not, however, examine the mechanisms underlying the
decrease.
In this study we investigate whether antiviral factors can
explain the change in virus infectivity observed in experiments.
Briefly, we hypothesize that donor’s ramp-up-stage plasma
transferred into the recipient animal contains mostly free virus.
By contrast, donor’s set-point-stage plasma transferred into
the recipient animal contain a large amount of antibody-virus
immune complexes in addition to free virus. If such immune
complexes can still infect, then their infectivity rate is reduced
compared to that of the free virus. To test this hypothesis, we
develop a mathematical model of antibody-virus dynamics that
assumes interaction between virus, recipient and donor antibody,
and the corresponding immune complexes. We fit the model
to viral load data from two recipient animals challenged with
donor’s ramp-up-stage plasma, three challenged with donor’s
set-point-stage plasma, and one infused with donor’s set-point
antibody and challenged with donor’s ramp-up-stage plasma.
The fits give us parameter estimates for long-run antibody
concentration, free virus infectivity rates, and the relation
between protection and free virus - immune complex ratio in the
inoculum.
METHODS
Data
We are using published data from the Ma et al. (2009) (all
information regarding approvals by IRB can be found in the
original study). Briefly, plasma samples from seven SIV infected
rhesus macaques were collected during the ramp-up and set-
point-stages of infections. Various amounts of vRNA were
titrated from the two plasma pools and used for intravenous
infection of SIV naive rhesus macaques (see Ma et al., 2009
for additional details). Animals 35036, 33815, and 3297 were
challenged with virus from ramp-up-stage plasma and animals
33952, 34846, and 34373 were challenged virus from set-
point-stage plasma. Lastly, animals 33681, 32350, 32970, and
36068 were challenged with virus from an aliquot of ramp-up-
stage plasma containing heat inactivated set-point-stage plasma.
Longitudinal virus load data (vRNA copies per ml) was collected
for all recipient animals that became viremic.
Model of Recipient-Virus Interaction
We develop a mathematical model of virus-antibody interaction
that investigates the connection between inoculum size and
disease outcome. We start with the basic SIV model (Perelson
et al., 1996; Bonhoeffer et al., 1997) which considers the
interaction between activated uninfected CD4 T cells T, infected
CD4 T cells I, and free virus V , as follows
dT
dt
= s− dT − βTV ,
dI
dt
= βTV − δI,
dV
dt
= NδI − cV .
(1)
Uninfected cells are produced at rate s, die at per capita rate d,
and become infected upon encountering virus at rate β . Infected
cells die at per capita rate δ and produce N virions throughout
their average lifespan. Free virus is eliminated at per capita rate c.
During challenge with donor’s plasma, we assume that donor’s
antibody AD and donor’s virus-antibody immune complexes
XD are transferred into the recipient animals. AD decays
exponentially at rate dA. We assume that donor’s immune
complexes XD can still infect target cells at rate β1. Their
infectivity rate, however, is smaller than that of free virus, β1 < β .
XD unbind to give rise to free virus
XD
km
⇋
kp
V + AD, (2)
where kp and km are binding and unbinding rates. Lastly, XD
are cleared faster than free virus. We model this in a density
dependent manner, with cAV being the maximum removal rate
andM the complexes at which the removal is half-maximal.
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We next assume that a de novo antibody response to the SIV
infection occurs in recipients. Recipient antibody, AR, binds free
virus, V , and forms antibody-virus immune complexes, XR
AR + V
km
⇋
kp
XR, (3)
with the same binding and unbinding rates as the those of
the donor antibody. Recipient antibody expands in an antigen
dependent manner at rate α. We account for immunological
memory by assuming that recipient antibodies persist in an
antigen independent manner with maximum proliferation r and
carrying capacity K. Recipient immune complexes have the same
infectivity rate, β1 < β , and the same removal rate, cAV > c, as
the donor’s immune complexes.
The model becomes
dT
dt
= s− dT − βTV − β1T(XD + XR),
dI
dt
= βTV + β1T(XD + XR)− δI,
dV
dt
= NδI − cV − kp(AR + AD)V + km(XR + XD),
dAR
dt
= αARV + rAR
(
1−
AR
K
)
− kpARV + kmXR,
dXR
dt
= kpARV − kmXR − cAV
XR
XR +M
,
dAD
dt
= −dAAD − kpADV + kmXD,
dXD
dt
= kpADV − kmXD − cAV
XD
XD +M
,
(4)
with initial values T(0) = s/d, I(0) = 0, V(0) = V0 > 0,
AR(0) = A0, XR(0) = 0, AD(0) ≥ A0 and XD(0) ≥ 0.
Parameter Values and Initial Conditions
We assume that we have T(0) = 106 per ml and I(0) = 0
per ml at the beginning of infection. Uninfected CD4 T cells are
produced at rate s = 104 per ml per day (Sachsenberg et al., 1998)
and die at rate d = 0.01 per day (Stafford et al., 2000). We use
previous estimates for the infected cells death rate, δ = 0.39 per
day (Markowitz et al., 2003), virus clearance rate, c = 23 per day
(Ramratnam et al., 1999), and virus production by an infected
cells, N = 2,000 per day (Ciupe, 2015). We fix the immune
complexes infectivity rate β1 = 10
−8 ml per day per virion.
Since all donor and recipient animals were negative for
anti-SIV antibodies, we assume the antibodies are below their
limit of detection of 3.8 × 108 molecules per ml (0.1 ng/ml1).
Without loss of generality, AD(0) = AR(0) = 3.5 × 10
8
molecules per ml. The recipient immune complexes are absent
at the time of infection, XR(0) = 0 molecules per ml. Donor
antibodies decay at rate dA = 0.07 per day (Zalevsky et al.,
2010). Once infection occurs, recipient antibodies are produced
and expand in both virus-dependent and virus-independent
1IgG Human ELISA Kit ab100547. http://www.abcam.com/IgG-Human-ELISA-
Kit-ab100547.html.
manners, at rates α and r, respectively. Since α and r have
complementary functions (see Supplementary Material), we can
ignore one of them. For simplicity, we set α = 0. Immune
complexes dissociate at rate km = 100 per day (Schwesinger
et al., 2000; Zhou et al., 2007; Tabei et al., 2012). The IgG affinity
KA = kp/km in a humoral response frequently starts at 10
5
M−1 (Gopalakrishnan and Karush, 1975). For SIV, each virion
can have ten to hundreds of potential antibody binding sites and
affinity maturation may occur. Taking both effects into account
can increase the functional affinity KA to 10
8 M−1. Therefore,
we consider a binding rate kp = KA × km = 10
10M−1/day=
1.6 × 10−11 ml per molecule per day, higher than in Tabei et al.
(2012), Ciupe (2015) and a carrying capacity K = 5 × 1013
molecules per ml. We assume that a maximum of cAV = 10
6
immune complexes are removed per day, and that the removal
rate is half-maximal forM = 500 immune complexes.
When an animal is challenged with SIV, the inoculum plasma
may contain both free virus or donor’s immune complexes.
As in Vaidya et al. (2010), we assume that the initial virus
distributes throughout the entire plasma volume of a 7 kg
macaque, approximately 300ml. Therefore, our initial conditions
are XD(0) + V(0) = D(0)/300 copies per ml, where D(0) is the
inoculum vRNA (Ma et al., 2009), and V(0) and XD(0) vary.
We assume that the free virus infectivity rate β(> β1) ml per
day per virion, antibody carrying capacity K molecules per ml,
and antibody independent expansion rate r per day are unknown
and we estimate them through data fitting. All fixed parameters
and initial conditions are presented in Table 1.
Data Fitting
We estimate parameters β and r by simultaneously fitting
VT(t) = V(t) + XD(t) + XR(t) given by model (4) with known
total virus initial conditions to both chronic and no-infection
virus data. Twomonkeys (35036 and 33815) were protected when
challenged with 2 ramp-up vRNA and chronically infected when
challenged with 20 ramp-up vRNA. We use these to get initial
concentrations of VT(0) = 2/300 and VT(0) = 20/300 copies
per ml, respectively. When a monkey is protected, no vRNA
data is collected. We create an artificial data set VTiterlow =
{2/300, 1/300} copies per ml at times τj ∈ {0, 30} days in
each animal that did not get infected. When a monkey gets
infected, total virus concentrations VTiterhigh(ti) above the limit
of detection were collected at ti ∈ {2, 5, 7, 9, 12, 14, 21, 28} days
post infection for each subject.
Similarly, three monkeys (33952, 34846, and 34373) were
protected when challenged with 1.5, 15, and 150 set-point vRNA
and chronically infected when challenged with 1500 set-point
vRNA. We therefore use initial concentrations VT(0) = 150/300
and VT(0) = 1,500/300 copies per ml for VT(0) in model (4).
When a monkey is protected, no vRNA data is collected. We
create an artificial data set VTiterlow = {150/300, 1/300} copies
per ml at times τj ∈ {0, 30} days in each animal that did not get
infected.When amonkey gets infected, total virus concentrations
VTiterhigh(ti) above the limit of detection were collected at ti ∈
{5, 7, 9, 12, 14, 21, 28} days post infection for subjects 33952 and
34373, and ti ∈ t¯ = {14, 21, 28} days post infection for subject
34846.
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TABLE 1 | Parameter values and initial conditions used in model (4).
Variables Description Initial values
T Target cells (cells ml−1) T (0) = 106
I Infected cells (cells ml−1) I(0) = 0
V Free virus (virion ml−1) V (0) varies
AD Donor antibody (molecules ml
−1) AD(0) varies
AR Recipient antibody (molecules ml
−1) AH (0) = 3.5× 10
8
XD Donor immune complexes (complexes ml
−1 ) HD(0) varies
XR Recipient immune complexes (complexes
ml−1)
HX (0) = 0
Parameters Description Values
s CD4 T cell production rate (cells ml-day−1) 104
d Target CD4 T cells death rate (day−1) 0.01
β Free virus infectivity rate (ml day-virion−1) estimated
β1 Immune complexes infectivity rate (ml
day-virion−1)
10−8
δ Infected cells death rate (day−1) 0.39
N Burst size (virion) 2000
c Virus clearance rate (day−1) 23
α Antigen dependent expansion of antibodies
(ml day-virion−1)
10−9
r Antibody division rate (day−1) estimated
dA Antibody degradation rate(day
−1) 0.07
K Antibody carrying capacity (molecules ml−1 ) 5× 1013
kp Binding rate (ml day-virion
−1) 1.6× 10−11
km Unbinding rate (day
−1) 100
cAV Immune complexes clearance rate
(complexes day−1)
106
M Immune complexes where clearance is half
maximal (ml−1)
500
We use the “fminsearch” algorithm in MATLAB R2016b [The
MathWorks Inc., Natick, MA] to minimize the functional
J(β ,K, r) =
(
n∑
i=1
(
logVT(ti)− logVTiterhigh(ti)
)2
+
2∑
j=1
(
logVT(τj)− logVTiterlow(τj)
)2
1/2
, (5)
where n is the number of data points. Finally, VT(ti) and VT(τj)
are the theoretical predictions for the total viral concentration as
given by model (4) at times ti and τj.
RESULTS
Antibody-Dependent Basic Reproduction
Number
The model exhibits bistable switch between a clearance state
S0 = (s/d, 0, 0,K, 0, 0, 0) and a positive chronic state S1 =
(T1, I1,V1,AR1,XR1, 0, 0). We can show analytically that steady
state S0 is locally asymptotically stable when R
a
0 < 1 (see
Supplementary Material), where
Ra0 = R0
km +
cAV
M +
β1
β
kpK
km +
cAV
M +
cAV
cM kpK
< 1. (6)
Inequality (6) shows that even if viremia occurs in the absence
of antibodies, R0 =
Nβs
dc
> 1, viral clearance can be reached
when the combined contribution of the protective and/or infused
antibodies make Ra0 < 1. We name R
a
0, the antibody-dependent
basic reproduction number, which represents the number of
virion produced in average by an infected cell in an otherwise
infection-free population throughout its lifetime when antibodies
are present.
Ra0 < 1 is a necessary but not sufficient condition for virus
clearance. Indeed, numerical results show that for Ra0 < 1, the
chronic state S1 is asymptotically stable as well. That means that
given Ra0 < 1 and appropriate initial conditions the chronic
steady state S1 can be reached. We numerically investigate the
relationship between the model’s initial conditions, animal data
and the model’s long-term behavior.
Infection With Ramp-Up-Stage Virus
Animals 35036 and 33815 were challenged with 20 vRNA copies
that were titrated from a plasma pool containing virus collected
from seven monkeys during the ramp-up-stage of infection
(defined as approximately 7 days after challenge). Following
challenge they became viremic. In contrast, animal 32970, who
was challenged 2 vRNA copies from the same plasma pool,
did not develop a persistent infection (Ma et al., 2009). Since
immune complexes are detected around 21 days post infection
(Tomaras et al., 2008; Liu et al., 2011), we assume that the
ramp-up inoculum contains only free virus. Therefore, our initial
concentrations are XD(0) = 0 and V(0) = 20/300 copies per
ml in animals 35036 and 33815; V(0) = 2/300 copies per ml in
animal 32970. The best estimates for β and r were obtained by
minimizing J given by (5) for the above initial conditions (see
Table 2).
Our model predicts a bistable switch in the virus dynamics
between persistence and clearance when the free virus initial
concentration changes from 20/300 to 2/300 copies per ml
(see Figure 1, left panels). For median estimates among the two
animals, we predict that for V(0) = 20/300 copies per ml, the
total virus load increases to a maximum of 2× 108 copies per ml,
before decreasing to equilibrium levels of 9 × 106 copies per ml,
three months after infection. By contrast, when V(0) = 2/300
copies per ml, the total virus concentration grows to 850 copies
per ml four days following infection, before it decays below the
limit of detection of 50 vRNA copies per ml.
The antibody populations do not depend of the initial viral
inoculum (see Figure 1, right panels). They reach maximum
carrying capacity 5 × 1013 molecules per ml (0.0125 mg per ml)
seven days after infection. When V(0) = 20/300 vRNA copies
per ml, free virions bind recipient antibodies to form recipient
immune complexes which, at equilibrium, exceed the free virus
concentration 7.8 times. When V(0) = 2/300 copies per ml,
immune complexes are formed, but they decay below limit of
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TABLE 2 | Parameter estimates and 95% confidence intervals from minimizing the likelihood function J given by (5) for the ramp-up data.
Animal β (ml day-virion−1) 95% CI r(day−1) 95% CI Ra
0
35036 1.58× 10−7 [1.57× 10−7, 1.59× 10−7] 2.32 [2.3, 2.33] 0.42
33815 1.34× 10−7 [1.33× 10−7, 1.35× 10−7] 1.95 [1.945, 1.952] 0.35
Median 1.46× 10−7 – 2.14 – –
FIGURE 1 | (Left) Basin of attraction for VT given by (4) vs. data; (Right) Free antibody (solid lines); recipient immune complexes (dashed lines) and donor immune
complexes (dotted lines) for V (0) = 20/300 vRNA copies per ml, XD(0) = 0 vRNA copies per ml (black) and V (0) = 2/300 vRNA copies per ml, XD(0) = 0 vRNA copies
per ml (gray). Note that antibody populations are identical regardless of initial conditions (solid black and gray lines overlap).
detection 7 days after inoculation. Model (4) assumed that B-
cell priming by the virus is followed by an antigen-independent
antibody expansion with a maximum per capita growth rate r.
We estimated a median per capita growth rate r = 2.14 per day,
corresponding to the doubling time of antibody population of
7.8 h.
We are interested in determining the largest initial virus
inoculum that allows for viral clearance under the ramp-up-
stage modeling assumptions. For the median r parameter in
Table 2we derived a bifurcation diagram showing the asymptotic
free virus concentrations three months following infection when
the infectivity rate β is varied (see Figure S1). The system
is displaying hysteresis. For the median infectivity rate β in
Table 2, we plotted the basins of attractions for the total virus
concentration VT when the inoculum concentration varies (see
Figure 2, left panel). We predict that VT is cleared for V(0) <
17.5/300 copies per ml and persists otherwise.
Infection With Set-Point-Stage Virus
Animals 33952, 34846, and 34373, were challenged with vRNA
copies titrated from a plasma pool containing virus collected
during the set-point-stage of infection (defined as the time several
months after the peak when plasma vRNA levels were relatively
stable, and antibody responses were well developed) of the seven
donor monkeys (Ma et al., 2009). The animals were protected
when challenged with set-point-stage plasma titrated to contain
1.5, 15, and 150 vRNA and became viremic when challenged
with set-point-stage plasma containing 1500 vRNA. We aim to
determine the parameter sets for which model (4) predicts a
switch between viral persistence for V(0) + XD(0) = 1500/300
copies per ml and clearance for V(0) + XD(0) = 150/300 copies
per ml (and consequently for 1.5/300 and 15/300 vRNA copies
per ml).
As before, we assume that the donor’s antibody concentration
is below the limit of detection. However, there are 7.8 times
more immune complexes than free virus in the inoculum plasma,
XD(0)/V(0) = 7.8, as predicted by the model (4) fitted to ramp-
up data and run to equilibrium values. We minimize functional
J given by (5) with XD(0)/V(0) = 7.8. The estimated parameters
are presented in Table 3.
We predict a bistable switch between persistent and cleared
virus populations based on initial conditions (see Figure 3,
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FIGURE 2 | VT given by (4) at steady state vs. i for: (Left) V (0) = i/300 vRNA copies per ml, XD(0) = 0 vRNA copies per ml and median parameters in Table 2;
(Right) V (0) = i/300 vRNA copies per ml, XD(0) = 7.8× i/300 vRNA copies per ml and median parameters in Table 3.
TABLE 3 | Parameter estimates and 95% confidence intervals from minimizing the likelihood function J given by (5) for the set-point data.
Animal β (ml day-virion−1) 95% CI r(day−1) 95% CI Ra
0
33952 9.3× 10−8 [9.23× 10−8, 9.33× 10−8] 1.37 [1.369, 1.375], 0.25
34846 4.09× 10−8 [4.07× 10−8, 4.1× 10−8] 0.515 [0.512, 0.518] 0.108
34373 1.07× 10−7 [9.51× 10−8, 1.07× 10−7] 1.66 [1.5, 1.8] 0.2673
Median 9.3× 10−8 – 1.37 – –
left panels). The median set-point virus infectivity rate is 1.5
times smaller than the median infectivity rate of the animals
infected with the ramp-up-stage plasma. Moreover, the median
set-point antibody antigen-dependent growth rate, r is 1.55
times smaller, corresponding to a median antibody population’s
doubling time of 12 h. We decided to compare median values,
rather than averages, since the set-point plasma results are
biased by the estimates in animal 34846 whose virus growth is
delayed.
We next quantified the largest initial virus inoculum that
allows for viral clearance when the initial inoculum is comprised
of 7.8 times more immune complexes than free virion. We
set all parameters at the median values in Table 3 and plotted
the basins of attractions for the total virus concentration three
months following infection as the inoculum concentration varies
(see Figure 2, right panel). We predict that VT is cleared when
VT(0) ≤ 42/300 vRNA copies per ml, XD(0)/V(0) = 7.8 and
persists otherwise. We also investigated the relation between viral
clearance, VT(0) and the ratio XD(0)/V(0). We note that when
the ratio between the immune complexes and free virus in the
initial plasma is low, even a small inoculum size can create virus
persistence. Conversely, when the immune complexes dominate
the initial plasma, a large initial virus inoculum is needed to
establish an infection (see Figure 4).
Infection With a Mix of Heat Inactivated
Set-Point-Stage Plasma Mixed With
Ramp-Up-Stage Virions
To determine whether antibodies play a role in reducing
virus infectivity, Ma et al. designed an aliquot of ramp-up
stage plasma containing 20 vRNA/0.5 ml mixed with 0.5 ml
of heat inactivated set-point-stage plasma (Ma et al., 2009).
The set-point-stage plasma contained antibodies capable of
in vitro neutralization. They used the aliquot on four animals:
33681, 32350, 32970, and 36068, with the first three animals
being protected and the last animal developing persistent
infection.
To address this experimental setting we assume the model
follows the dynamics given by median parameter values in the
ramp-up case with V(0) = 20/300 copies per ml and XD(0) =
0 copies per ml (see Tables 1, 2). However, we vary AD(0) to
account for donor’s antibody being present in the inoculum. We
find that a minimum of AD(0) = 7.4 × 10
9 donor antibody
molecules per ml (1.8×10−6 mg perml) are needed for clearance.
This value is above the antibody’s limit of detection, but more
than three orders of magnitude below the antibody’s equilibrium
values. This suggests that even low antibody levels may help
protect the host.
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FIGURE 3 | (Left) VT given by (4) vs. data; (Right) Free antibody (solid lines), recipient immune complexes (dashed lines) and donor immune complexes (dotted lines):
for V (0)+ XD(0) = 1500/300 vRNA copies per ml, XD(0)/V (0) = 7.8 (black) and V (0)+ XD(0) = 150/300 vRNA copies per ml, XD(0)/V (0) = 7.8 (gray). Note that
antibody populations are identical regardless of initial conditions (solid black and gray lines overlap) but the immune complexes differ.
FIGURE 4 | Asymptotic behavior for the VT solutions of (4) for median parameters in Table 3 as the initial vRNA and XD(0)/V (0) are varied. The blue region (left of the
curve) corresponds to extinction asymptotic concentrations VT = 0 copies per ml. The yellow region (right of the curve) corresponds to persistence asymptotic
concentrations VT = 6.9× 10
6 copies per ml.
Frontiers in Microbiology | www.frontiersin.org 7 June 2018 | Volume 9 | Article 1216
Ciupe et al. Bistable Virus Dynamics in SIV Infections
Wewant to determine the additional recipient-virus dynamics
that lead to infection in animal 36068. We fit VT given by model
(4) with V(0) = 20/300 vRNA copies per ml, XD(0) = 0 vRNA
copies per ml and AD(0) = 7.4× 10
9 molecules per ml to animal
36068’s virus data and found that virus persistence is due to the
recipient antibody dynamics (see Figure 5, right panel). Indeed,
for a good fit we need to decrease the recipient’s antibody carrying
capacity to K = 5 × 1012 molecules per ml, 10 times lower than
the previous carrying capacity in ramp-up infected animals. The
antigen-independent expansion rate r = 1.62 per day is 1.3 times
smaller than the median per capita antibody expansion rate in
the ramp-up infected animals, but similar to that of set-point
infected animals (see Table 4). This implies that animal’s 36068
immune response is not strong enough to prevent persistent
viremia. Moreover, for these antibody parameters bistability does
not occur (Ra0 = 2.26 > 1), and the virus reaches a positive
steady state level regardless of the size and structure of the initial
inoculum.
Can Random Infection and Clearance
Events Explain the Data?
To address whether the switch in virus dynamics is due to
random effects, we use the stochastic model of virus infection
and clearance developed in Pearson et al. (2011). Under the
parametrization of model (1), the burst stochastic model in
Pearson et al. (2011), is given by
V
βT
−→ I,
I
δ
−→ NV ,
V
c
−→ ∅.
(7)
Let n = (nV , nI) be the number of viruses and infected cells
starting the SIV infection,
ρV = Pr{Extinction|n = (1, 0)} and
ρI = Pr{Extinction|n = (0, 1)}, (8)
be the probabilities of extinction given an infection that is started
by one virus or one infected cell. Then the probability of virus
persistence given nV virion and nI infected cells, ǫ = 1−ρ
nV
V ρ
nI
I ,
can be computed analytically. Namely
ρV = min{1, ρ
∗
V},
ρI = min{1, (ρ
∗
V )
N},
(9)
where ρ∗V is the positive solution of the equation
γ (ρV )
N − ρV + 1− γ = 0. (10)
Note that the probability of persistence ǫ is dependent on the
burst size N and on the probability that a virus infects a cell,
γ =
βT
βT+c (see Pearson et al., 2011 for a full derivation). For
fixed N = 300 virions per infected cell, T = 106 cells per ml, and
c = 23 per day, we determine the infectivity values β that can
explain the relationship between extinction/persistence and the
inoculum size in ramp-up/set-point vRNA cases when free virus
establishes the infection, i.e., nI = 0 (see Figure 6).
We find that a 99% probability of persistence for a ramp-
up-stage inoculum of 20 vRNA occurs when the infectivity rate
β > 8 × 10−6, while the same persistence probability for a set-
point inoculum of 1500 vRNA occurs for β > 1.15 × 10−7 (see
Figure 6, red circles). For these choices of β , the probability of
extinction for the lower 2 ramp-up stage and 150 set-point-stage
vRNA inoculum are 64% and 65%, respectively (see Figure 6,
FIGURE 5 | (Left) VT given by (4) vs. data; (Right) Free antibody (solid lines), recipient immune complexes (dashed lines) and donor immune complexes (dotted lines)
for V (0) = 20/300 vRNA copies per ml, XD(0) = 0 vRNA copies per ml and AD(0) = 7.4× 10
9 molecules per ml.
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TABLE 4 | Parameter estimates and 95% confidence intervals from fitting VT to animal data for V (0) = 20/300 vRNA copies per ml, XD(0) = 0 vRNA copies per ml and
AD(0) = 7.4× 10
9 molecules per ml.
Animal β (ml day-virion−1) 95% CI r(day−1) 95% CI Ra
0
363068 1.11× 10−7 [1.06× 10−7, 1.17× 10−7] 1.62 [1.5, 1.74] 2.26
FIGURE 6 | The probability of virus persistence for (Left) ramp-up-stage and (Right) set-point-stage vRNA data under the assumption of the burst stochastic model
(7). The red circles account for the probability of persistence for high inocula, while the blue stars account for the probability of persistence for low inocula.
blue stars). In order for the proposed stochastic process to
explain the experimental observations, there must be a 70-fold
reduction in the infectivity rate β between ramp-up and set-
point virus (8.75 times higher than estimated in Vaidya et al.,
2010). Moreover, the extinction probability for the lower inocula
is lower than ideal. While the stochastic explanation is still
conceivable, we conclude that the presence of immune complexes
in the inoculum is a compelling alternative explanation for the
experimental outcomes.
DISCUSSION
We developed a mathematical model of antibody responses to
SIV infection that shows a bistable switch between persistent
infection and virus clearance based on the composition of the
plasma used for intravenous inoculation.
We made several interesting observations. When the plasma
does not contain any free donor antibody, our model predicts
that the difference between infection with high inoculum
containing set-point-stage virus and infection with low inoculum
containing ramp-up-stage virus can be explained by the presence
of immune complexes in the inoculum that exceed free virus by
a factor of 7.8. Such immune complexes can still infect target
CD4 T cells, but have a 10-fold decrease in infectivity. Under
these assumptions, the model fits the data when the infectivity
of free virus is constant over time. There is a 1.5-fold decrease in
the set-point-stage free virus infectivity compared to ramp-up-
stage free virus infectivity, as reported in earlier studies (Ma et al.,
2009; Vaidya et al., 2010). Such decrease may be due to temporal
accumulation of non-infectious particles and to the emergence of
other immune factors such as CD8 T cell responses.
When the inoculum plasma contains neutralizing antibody,
our model predicts that infection is blocked even when free virus
infectivity rates are as high as in the ramp-up stage. In order for
virus to invade, antibody responses need to be 10 times lower at
equilibrium. Moreover, their growth needs 1.3-fold reduction.
We assumed that the recipient and donor antibody have high
avidity of 108 M−1 (as with infusion of broadly neutralizing
antibody), a high antibody carrying capacity K = 5 × 1013
molecules per ml and estimated the recipient antibody expansion
rate needed for protection. With our model, however, it is
difficult to separate out the effects of changing the avidity rate
KA = kp/km and changing the antibody carrying capacity K. For
example we can preserve the results by decreasing avidity and
increasing the carrying capacity. Similarly, the antibody antigen-
dependent and antigen-independent growth factors, r and α,
have synergistic effects. If we decrease r we can maintain the
overall virus-antibody dynamics by increasing α (as detailed in
the sensitivity Figure S2).
We have also assumed that the immune complexes infect at
rate β1 = 0.1 × β ml per day per virion. This was an arbitrary
choice, and the estimated infectivity rate β may change when the
β to β1 ratio is varied.
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An important variable in our study is the basic reproduction
number Ra0, which has to remain below one for viral clearance.
However, even when Ra0 < 1, a persistent infection can still occur
when either inoculum is composed of mostly free virion, free
virus infectivity rate is high, and/or equilibrium antibody levels
are low. The presence of bistable switch allows us to alter the
infection outcome in the model by changing the initial antibody
levels. Knowing the minimum antibody concentration needed to
prevent viremia under fixed parameter setting is important for
guiding vaccine design.
To address whether stochastic effects alone can explain
the data, we computed the probability of virus persistence
under the assumption of a burst stochastic model developed
in Pearson et al. (2011). We find that a 70-fold decrease in
virus infectivity rate β is needed between the ramp-up and
set-point-inoculum in order to obtain a 99% probability of
persistence for a ramp-up inoculum of 20 vRNA and a set-
point inoculum of 1500 vRNA occurs. This is higher than the
8-fold decrease reported in Vaidya et al. (2010). Furthermore,
the extinction probabilities for the lower ramp-up inoculum of
2 vRNA and a set-point inoculum of 150 vRNA, 64% and 65%,
are lower than ideal. While the stochastic explanation is still
conceivable, we conclude that the presence of immune complexes
in the inoculum is a possible alternative explanation for the
experimental outcome.
Our study uses data from an intravenous inoculation
experiment. It is not clear if a similar relationship exist
with mucosal virus inoculation or with non-neutralizing
antibody responses. In fact, some antibody responses were
associated with enhanced risk of heterosexual HIV acquisition in
RV144. Further, immune-complexed virus may be preferentially
transported across epithelial surfaces by the neonatal Fc
receptor (Haynes, 2012; Gorlani and Forthal, 2013; Gupta
et al., 2013, 2015). Our analysis focused only on the role of
antibody in infectivity after any epithelial barriers had been
crossed.
In summary, we have developed a model of virus-host
dynamics during SIV infection that gives insight into the relation
between the structure of infecting inoculum, virus infectivity and
disease outcomes. In particular, we showed that a large set-point-
stage inoculum is needed for persistent infection due to the excess
of immune complexes over the free virus. Moreover, we have
estimated the antibody levels and the free virus infectivity and
their relation to the disease outcome when the inoculum size and
structure are well understood. Such predictions are important for
vaccine design.
AUTHOR SUMMARY
We investigate whether antiviral factors can explain the change
in virus infectivity during acute and chronic stages of simian
immunodeficiency virus infections. Our hypothesis is that
acute plasma contains mostly free virus while chronic plasma
contains antibody-virus immune complexes in addition to free
virus. If such immune complexes can still infect, then their
infectivity rate is reduced compared to that of the free virus.
We test this hypothesis by developing a mathematical model
of antibody-virus dynamics that assumes interactions between
virus, recipient and donor antibodies, and the corresponding
immune complexes. We fit the model to published viral load data
from recipient rhesus macaques challenged intravenously with
different virus loads collected during donor’s acute and chronic
stages of SIV infection. The fits give us parameter estimates
for long-run antibody concentration, free virus infectivity rate,
and the relation between protection and the free virus—immune
complexes ratio in the inoculum.
AUTHOR CONTRIBUTIONS
SC and JF designed the study and performed numerical
experiments. CM provided the data. SC, CM, and JF wrote the
paper.
ACKNOWLEDGMENTS
SC acknowledges support fromNSF grants DMS-1214582, DMS-
1813011, Simons Foundation grant 427115 and VT’s OASF. CM
was supported by Public Health Services grants U51RR00169,
from the National Center for Research Resources; and P01
AI066314 from the National Institute of Allergy and Infectious
Diseases. We are grateful to Dr Honghu Li for valuable
discussions.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fmicb.
2018.01216/full#supplementary-material
REFERENCES
Bonhoeffer, S., May, R., Shaw, G., and Nowak, M. (1997). Virus dynamics
and drug therapy. Proc. Natl. Acad. Sci. U.S.A. 94, 6971–6976.
doi: 10.1073/pnas.94.13.6971
Ciupe, S. (2015). Mathematical model of multivalent virus-antibody complex
formation in humans following acute and chronic HIV infections. J. Math. Biol.
71, 513–532. doi: 10.1007/s00285-014-0826-3
Deal, C., and Balazs, A. (2015). Engineering humoral immunity as prophylaxis or
therapy. Curr. Opin. Immunol. 35, 113–122. doi: 10.1016/j.coi.2015.06.014
Gopalakrishnan, P., and Karush, F. (1975). Antibody affinity. VIII. measurement
of affinity of anti-lactose antibody by fluorescence quenching with a DNP-
containing ligand. J. Immunol. 114, 1359–1362.
Gorlani, A., and Forthal, D. (2013). Antibody-dependent enhancement
and the risk of HIV infection. Curr. HIV Res. 11, 421–426.
doi: 10.2174/1570162X113116660062
Gray, E., Madiga, M., Hermanus, T., Moore, P., Wibmer, C., Tumba, N., et al.
(2011). The neutralization breadth of HIV-1 develops incrementally over four
years and is associated with CD4+ T cell decline and high viral load during
acute infection. J. Virol. 85, 4828–4840. doi: 10.1128/JVI.00198-11
Gupta, S., Gach, J., Becerra, J., Phan, T., Pudney, J., Moldoveanu, Z., et al. (2013).
The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus
type 1 (HIV-1) trancytosis across epithelial cells. PLoS Pathog. 9:e1003776.
doi: 10.1371/journal.ppat.1003776
Gupta, S., Pegu, P., Venzon, D., Gach, J., Ma, Z., Landucci, G., et al. (2015).
Enhanced in vitro transcytosis of simian immunodeficiency virus mediated
Frontiers in Microbiology | www.frontiersin.org 10 June 2018 | Volume 9 | Article 1216
Ciupe et al. Bistable Virus Dynamics in SIV Infections
by vaccine-induced antibody predicts transmitted/founder strain number after
rectal challenge. J. Infect Dis. 211, 45–52. doi: 10.1093/infdis/jiu300
Haynes, B. (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial.
N. Engl. J. Med. 366, 1275–1286. doi: 10.1056/NEJMoa1113425
Haynes, B. (2015). New approaches to HIV vaccine development. Curr. Opin.
Immunol. 35, 39–47. doi: 10.1016/j.coi.2015.05.007
Letvin, N., Rao, S., Montefiori, D., Seaman, M., Sun, Y., Lim, S.-Y.,
et al. (2011). Immune and genetic correlates of vaccine protection
against mucosal infection by SIV in monkeys. Sci. Transl. Med. 3:81ra36.
doi: 10.1126/scitranslmed.3002351
Liu, P., Overman, R., Yates, N., Alam, S., Vandergrift, N., Chen, Y., et al.
(2011). Dynamic antibody specificities and virion concentrations in circulating
immune complexes in acute to chronic HIV-1 infection. J. Virol. 85, 11196–
11207. doi: 10.1128/JVI.05601-11
Ma, Z., Stone, M., Piatak, M., Schweighardt, B., Haigwood, N., Montefiori, D.,
et al. (2009). High specific infectivity of plasma virus from the pre-ramp-up
and ramp-up stages of acute simian immunodeficiency virus infection. J. Virol.
83, 3288–3297. doi: 10.1128/JVI.02423-08
Markowitz, M., Louie, M., Hurley, A., Sun, E., Di Mascio, M., Perelson, A., et al.
(2003). A novel antiviral intervention results in more accurate assessment of
human immunodeficiency virus type 1 replication dynamics and T-cell decay
in vivo. J. Virol. 77, 5037–5038. doi: 10.1128/JVI.77.8.5037-5038.2003
Mascola, J., and Haynes, B. (2013). HIV-1 neutralizing antibodies: understanding
nature’s pathways. Immunol. Rev. 254, 225–244. doi: 10.1111/imr.12075
Mascola, J., Lewis, M., Stiegler, G., Harris, D., VanCott, T., Hayes, D., et al. (1999).
Protection of macaques against pathogenic simian/human immunodeficiency
virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–
4018.
Moldt, B., Rakasz, E., Schultz, N., Chan-Hui, P.-Y., Swiderek, K., Weisgrau,
K., et al. (2012). Highly potent HIV-specific antibody neutralization in vitro
translates into effective protection against mucosal SHIV challenge in vivo.
Proc. Natl. Acad. Sci. U.S.A. 109, 18921–18925. doi: 10.1073/pnas.1214785109
Nishimura, Y., Igarashi, T., Haigwood, N., Sadjadpour, R., Donau, O., Buckler,
C., et al. (2003). Transfer of neutralizing IgG to macaques 6 h but not
24 h after SHIV infection confers sterilizing protection: Implications for
HIV-1 vaccine development. Proc. Natl. Acad. Sci. U.S.A. 100, 15131–15136.
doi: 10.1073/pnas.2436476100
Pearson, J., Krapivsky, P., and Perelson, A. (2011). Stochastic theory of early viral
infection: continuous versus burst production of virions. PLoS Comput. Biol. 7,
1–17. doi: 10.1371/journal.pcbi.1001058
Perelson, A., Neumann, A., Markowitz, M., Leonard, J., and Ho, D. (1996). HIV-
1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral
generation time. Science 271, 1582–1586. doi: 10.1126/science.271.5255.1582
Plotkin, S. (2008). Vaccines: correlates of vaccine-induced immunity. Clin. Infect.
Dis. 47, 401–409. doi: 10.1086/589862
Pollara, J., Bonsignori, M., Moody, M., Liu, P., Alam, S., Hwang, K.-K., et al.
(2014). HIV-1 vaccine-induced C1 and V2 env-specific antibodies synergize for
increased antiviral activities. J. Virol. 88, 7715–7726. doi: 10.1128/JVI.00156-14
Ramratnam, B., Bonhoeffer, S., Binley, J., Hurley, A., Zhang, L., Mittler, J.,
et al. (1999). Rapid production and clearance of HIV-1 and hepatitis C
virus assessed by large volume plasma apheresis. Lancet 354, 1782–1785.
doi: 10.1016/S0140-6736(99)02035-8
Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu,
J., Paris, R., et al. (2009). Vaccination with ALVAC and AIDSVAX to
prevent HIV-1 infection in Thailand. New Eng. J. Med. 361, 2209–2220.
doi: 10.1056/NEJMoa0908492
Sachsenberg, N., Perelson, A., Yerly, S., Schockmel, G., Leduc, D., Hirschel, B.,
and Perrin, L. (1998). Turnover of CD4 and CD8 T lymphocytes in HIV-
1 infection as measured by Ki-67 antigen. J. Exp. Med. 187, 1295–1303.
doi: 10.1084/jem.187.8.1295
Schwesinger, F., Ros, R., Strunz, T., Anselmetti, D., Guntherodt, H.-J., Honegger,
A., et al. (2000). Unbinding forces of single antibody-antigen complexes
correlate with their thermal dissociation rates. Proc. Natl. Acad. Sci. U.S.A. 97,
9972–9977. doi: 10.1073/pnas.97.18.9972
Stafford, M., Corey, L., Cap, Y., Daar, E., Ho, D., and Perelson, A. (2000). Modeling
plasma virus concentration during primary HIV infection. J. Theor. Biol. 203,
285–301. doi: 10.1006/jtbi.2000.1076
Tabei, S., Li, Y., Weigert, M., and Dinner, A. (2012). Model for competition from
self during passive immunization, with application to broadly neutralizing
antibodies for HIV. Vaccine 30, 607–613. doi: 10.1016/j.vaccine.2011.
11.048
Tomaras, G., Binley, J., Gray, E., Crooks, E., Osawa, K., Moore, P., et al.
(2011). Polyclonal B cell responses to conserved neutralization epitopes
in a subset of HIV-1-infected individuals. J. Virol. 85, 11502–11519.
doi: 10.1128/JVI.05363-11
Tomaras, G., Ferrari, G., Shen, X., Alam, S., Liao, H.-X., Pollara, J., et al. (2013).
Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope
blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U.S.A. 110,
9019–9024. doi: 10.1073/pnas.1301456110
Tomaras, G., Yates, N., Liu, P., Qin, L., Fouda, G., Chavez, L., et al. (2008).
Initial B-cell responses to transmitted human immunodeficiency virus type 1:
virion-binding immunoglobulin IgM and IgG antibodies followed by plasma
anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82,
12449–12463. doi: 10.1128/JVI.01708-08
Vaidya, N., Ribeiro, R., Miller, C., and Perelson, A. (2010). Viral dynamics
during primary simian immunodeficiency virus infection: effect of time-
dependent virus infectivity. J. Virol. 84, 4302–4310. doi: 10.1128/JVI.02
284-09
Walker, L., Huber, M., Doores, K., Falkowska, E., Pejchal, R., Julien, J.-P., et al.
(2011). Broad neutralization coverage of HIV by multiple highly potent
antibodies. Nature 477, 466–470. doi: 10.1038/nature10373
Zalevsky, J., Chamberlain, A., Horton, H., Karki, S., Leung, I., Sproule, T., et al.
(2010). Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol.
28, 157–159. doi: 10.1038/nbt.1601
Zhou, T., Xu, L., Dey, B., Hessell, A., Van Ryk, D., Xiang, S.-H., et al. (2007).
Structural definition of a conserved neutralization epitope on HIV-1 gp120.
Nature 445, 732–737. doi: 10.1038/nature05580
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Ciupe, Miller and Forde. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Microbiology | www.frontiersin.org 11 June 2018 | Volume 9 | Article 1216
